2010
DOI: 10.1200/jco.2010.28.15_suppl.4508
|View full text |Cite
|
Sign up to set email alerts
|

Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0
1

Year Published

2010
2010
2022
2022

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 52 publications
(19 citation statements)
references
References 0 publications
0
18
0
1
Order By: Relevance
“…Cabazitaxel in castration resistant prostate cancer progressing during or after docetaxel Docetaxel has been the standard fi rst-line chemotherapy for CRPC since 2004, based on evidence that it improved survival compared to mitoxantrone plus prednisone (MP) [3,4]. Cabazitaxel, a novel semi-synthetic taxane, selected to overcome the emergence of taxane resistance [5,6] has demonstrated a statistically signifi cant OS benefi t in patients with CRPC who progressed during or after docetaxel chemotherapy [7]. One of the key features of cabazitaxel is a low affi nity for the multidrug resistance transporter P-glycoprotein, and studies have shown activity in patients with taxane-resistant metastatic breast cancer.…”
Section: Denosumab Compared To Zoledronic Acid In the Treatment Of Pamentioning
confidence: 99%
“…Cabazitaxel in castration resistant prostate cancer progressing during or after docetaxel Docetaxel has been the standard fi rst-line chemotherapy for CRPC since 2004, based on evidence that it improved survival compared to mitoxantrone plus prednisone (MP) [3,4]. Cabazitaxel, a novel semi-synthetic taxane, selected to overcome the emergence of taxane resistance [5,6] has demonstrated a statistically signifi cant OS benefi t in patients with CRPC who progressed during or after docetaxel chemotherapy [7]. One of the key features of cabazitaxel is a low affi nity for the multidrug resistance transporter P-glycoprotein, and studies have shown activity in patients with taxane-resistant metastatic breast cancer.…”
Section: Denosumab Compared To Zoledronic Acid In the Treatment Of Pamentioning
confidence: 99%
“…2 Another taxane anticancer drug, cabazitaxel, was recently approved by the FDA as a combination therapy for prostate cancer treatment. 3 Despite their potent antitumor activity, paclitaxel and docetaxel cause undesirable side effects as well as drug resistance. 2 Thus, it was apparent in the early 1990s that it would be essential to develop new taxane anticancer agents with fewer side effects, enhanced activity against multidrug-resistant human tumors, and superior pharmacological properties.…”
Section: Discovery and Development Of Next-generation Taxoids Based Omentioning
confidence: 99%
“…In many of their clinical indications, paclitaxel or docetaxel is combined with one or more additional anticancer agents. Recently, another taxoid, cabazitaxel, was approved by the FDA for hormone-refractory prostate cancer in combination with prednisone [22]. In addition to these FDA-approved drugs, a number of novel taxoids are in various stages of clinical and preclinical development [23, 24].…”
Section: Introductionmentioning
confidence: 99%